H Lundbeck A/S v Sandoz Pty Ltd (No 2)

Link copied
Case Copied 13 min read

FEDERAL COURT OF AUSTRALIA

H Lundbeck A/S v Sandoz Pty Ltd (No 2) [2019] FCA 46

File numbers: NSD 647 of 2014
NSD 824 of 2016
Judge: JAGOT J
Date of judgment: 29 January 2019
Catchwords: DAMAGES – patent infringement – discount applied for substitutable products – discount involves estimation – discount applied as part of overall discount for risk in respect of hypothetical profits
Cases cited: H Lundbeck A/S v Sandoz Pty Ltd [2018] FCA 1797
Date of hearing: Decided on the papers
Date of last submissions: 19 December 2018
Registry: New South Wales
Division: General Division
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Category: Catchwords
Number of paragraphs: 16
Counsel for H Lundbeck A/S, Lundbeck Australia Pty Ltd and CNS Pharma Pty Ltd: AJL Bannon SC with KJ Howard SC, LA Merrick and C Cunliffe
Solicitor for H Lundbeck A/S, Lundbeck Australia Pty Ltd and CNS Pharma Pty Ltd: Corrs Chambers Westgarth
Counsel for Alphapharm Pty Ltd, Apotex Pty Ltd and Aspen Pharma Pty Ltd: DKC Catterns QC with S Habib SC, C Dimitriadis SC, N Murray SC, AR Lang and B Mee
Solicitor for Alphapharm Pty Ltd, Apotex Pty Ltd and Aspen Pharma Pty Ltd: King & Wood Mallesons
Counsel for Sandoz Pty Ltd: JM Hennessy SC with PL Arcus and J Adamopoulos
Solicitor for Sandoz Pty Ltd: Clayton Utz

ORDERS

NSD 647 of 2014
BETWEEN:

H LUNDBECK A/S

First Applicant

LUNDBECK AUSTRALIA PTY LTD (ACN 070 094 290)

Second Applicant

AND:

SANDOZ PTY LTD (ACN 074 449 553)

Respondent

JUDGE:

JAGOT J

DATE OF ORDER:

29 JANUARY 2019

THE COURT ORDERS THAT:

1.The parties confer and file agreed or competing proposed orders finalising the matter, including as to costs, within 14 days of the date of these orders.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


ORDERS

NSD 824 of 2016
BETWEEN:

CNS PHARMA PTY LTD (ACN 121 515 400)

Applicant

AND:

SANDOZ PTY LTD (ACN 075 449 553)

Respondent

JUDGE:

JAGOT J

DATE OF ORDER:

29 JANUARY 2019

THE COURT ORDERS THAT:

1.The parties confer and file agreed or competing proposed orders finalising the matter, including as to costs, within 14 days of the date of these orders.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

JAGOT J:

  1. One outstanding issue in this matter concerns an aspect of the discount I concluded should be applied to the assessment of damages.

  2. In my principal reasons for judgment, H Lundbeck A/S v Sandoz Pty Ltd [2018] FCA 1797, I said this:

    419 The overall effect of this evidence is this. Doctors prescribe the antidepressant that they think will be clinically appropriate for the particular patient. In practice, provided the antidepressant is PBS listed (which Lexapro was), cost is not an issue. This is so whether or not there is a generic equivalent product.

    420 For these reasons, Sandoz’s submissions are over-stated. If…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read H Lundbeck A/S v Sandoz Pty Ltd (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2019] FCA 46
Decision Date

CaseChat Overview and Summary

The case before the Federal Court of Australia was between H Lundbeck A/S, a pharmaceutical company, and Sandoz Pty Ltd, a generic drug manufacturer. The dispute centred around patent infringement, specifically the infringement of a patent held by H Lundbeck for its antidepressant drug, Cipralex. Sandoz had manufactured and sold a generic version of Cipralex, leading H Lundbeck to seek damages for the infringement. The primary legal issues in the case were the calculation of damages and the appropriate discount to apply to the profits that H Lundbeck claimed it would have made had the infringement not occurred.

The court needed to decide whether a discount should be applied to the hypothetical profits for the generic version of the drug, considering that it was a substitutable product. The Federal Court examined the principles of damages for patent infringement and the precedent set by previous cases. It found that a discount was appropriate but also acknowledged the difficulty in precisely estimating the extent of the discount. The court decided that the discount should be applied as part of the overall discount for the risk inherent in the hypothetical profits calculation. This approach balanced the need to compensate H Lundbeck for the infringement with the inherent uncertainties in estimating future profits.

In conclusion, the Federal Court held that a discount should be applied to the hypothetical profits claimed by H Lundbeck, reflecting the substitutability of the generic product. The court directed the parties to confer and file agreed or competing proposed orders finalising the matter, including as to costs, within 14 days of the date of these orders. The specific amount of the discount and the final orders were to be determined by the parties in consultation.

Orders

Orders of the court

1. The parties confer and file agreed or competing proposed orders finalising the matter, including as to costs, within 14 days of the date of these orders.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.